Ortho-Clinical gets rights to Roche cardiac assay
This article was originally published in Clinica
Executive Summary
Roche Diagnostics has agreed to license to Ortho-Clinical Diagnostics, a Johnson & Johnson company, non-exclusive patent rights to its immunoassay technology designed to detect NT-proBNP (N-terminal prohormone brain natriuretic peptide), a key marker for congestive heart failure (CHF).